India Biopharmaceutical Market Outlook to 2028

India Biopharmaceutical Market Overview

The India Biopharmaceutical market is valued at USD 53 billion, driven by a combination of increasing healthcare needs, rising R&D investments, and strong government initiatives aimed at bolstering the biotechnology sector. The market growth is primarily fueled by the rising prevalence of chronic diseases, increasing investments in biologics, and the countrys growing capacity for research and innovation in the pharmaceutical and biotechnology sectors. The market is characterized by substantial investments in biosimilars and biologics, particularly in oncology, autoimmune diseases, and vaccines. This robust infrastructure positions India as a key player in the global biopharma landscape.

The biopharmaceutical market is dominated by cities like Hyderabad and Bangalore, known for their advanced biotechnology hubs and the presence of numerous pharmaceutical giants. Hyderabad, home to Genome Valley, a biotechnology cluster, and Bangalore, with its burgeoning startup ecosystem in life sciences and healthcare technology, have attracted investments from both domestic and international companies. These cities benefit from government support, a strong workforce of skilled scientists, and proximity to top research institutions, making them critical to the market's expansion.

India's National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential biopharmaceuticals, ensuring affordability. In 2023, the NPPA capped the prices of 34 critical biologics, including treatments for cancer and diabetes, to make them accessible to a larger population. While this ensures patient access, it poses a challenge to manufacturers in balancing profitability and compliance with pricing controls.

India Biopharmaceutical Market Segmentation

By Product Type: The India Biopharmaceutical market is segmented by product type into monoclonal antibodies, vaccines, gene therapies, recombinant proteins, and hormones. Recently, monoclonal antibodies have held a dominant market share due to their critical role in treating cancer, autoimmune diseases, and inflammatory conditions. The widespread use of these targeted therapies is driven by advancements in precision medicine, combined with their high success rates in clinical trials and the increasing approval rates by regulatory bodies. Furthermore, the demand for biosimilars and biobetters is rising, further cementing their market leadership.

By Application: The market is segmented by application into oncology, autoimmune diseases, neurology, infectious diseases, and metabolic disorders. Oncology dominates the application segment, primarily due to the rise in cancer incidences in India, and the need for innovative therapies. Biopharmaceutical treatments in oncology are highly effective due to their targeted approach, which reduces side effects compared to traditional chemotherapy. Major pharmaceutical companies are investing heavily in oncology research, further boosting the segment's growth and market share.

India Biopharmaceutical Market Competitive Landscape

The India biopharmaceutical market is dominated by a mix of domestic and international players, with companies focused on R&D, manufacturing, and commercialization. Several key players have established research facilities and manufacturing capacities, benefiting from government policies like the 'Make in India' initiative and investment in biotechnology clusters like Genome Valley. The competition is shaped by innovation in biosimilars, strategic partnerships, and collaborations with research institutions.

Company

Year Established

Headquarters

No. of Employees

R&D Investment (USD)

Key Product Segment

Global Presence

Revenue from Biopharma (USD)

Biocon Limited

1978

Bangalore-----

Dr. Reddys Laboratories

1984

Hyderabad-----

Sun Pharmaceutical

1983

Mumbai-----

Serum Institute of India

1966

Pune-----

Cipla Limited

1935

Mumbai-----

India Biopharmaceutical Market Analysis

India Biopharmaceutical Market Growth Drivers

Increasing Prevalence of Chronic Diseases: The prevalence of chronic diseases such as diabetes, cardiovascular diseases, and cancer is indeed a major driver for the biopharmaceutical market. As of 2024, India has over77 million diabetics, making it the second-highest globally.Additionally, cancer cases exceeded1.39 millionin 2023, and cardiovascular diseases accounted for 28%of all deaths in the country, as reported by the World Health Organization.This growing burden necessitates advanced biopharmaceutical treatments like monoclonal antibodies and personalized medicine, which aim to improve patient outcomes.

Rising Healthcare Expenditure: India's healthcare expenditure is on the rise, supporting its growing healthcare needs. The government's budget for healthcare was INR 2.23 trillion(around$27 billion) in 2023, reflecting a15.6%increase from previous years.This increase is aimed at enhancing healthcare infrastructure and innovation, including biopharmaceutical development. However, it's important to note that while the budget has increased, public health expenditure as a percentage of GDP remains relatively low at around2.1%for FY23.

Growth of Personalized Medicine: The demand for personalized medicine is indeed growing due to advancements in genomics and biomarker research. In 2023, it was reported that over40%of cancer treatments in urban centers utilized targeted therapies.Initiatives like the Genome India Project, which aims to sequence the genomes of over10,000 individuals, are contributing to this growth by identifying disease-specific biomarkers that enable customized treatments.

India Biopharmaceutical Market Challenges

High Manufacturing Costs: Biopharmaceutical manufacturing remains expensive due to the complex processes involved, including fermentation, purification, and cold-chain logistics. In India, the cost of establishing a biopharma manufacturing facility ranges from INR 500 crore to INR 1,000 crore ($60-$120 million), making it a growth barrier for new entrants. The need for specialized equipment and highly skilled personnel further escalates costs, challenging the scalability of biopharma companies, particularly for smaller firms.

Complex Regulatory Approvals: The regulatory landscape for biopharmaceuticals in India is complex and time-consuming. On average, the approval process for a new biologic drug takes 2-4 years, with multiple rounds of clinical trials required to meet the stringent guidelines of the Central Drugs Standard Control Organization (CDSCO). In 2023, over 60 biosimilars awaited approval, reflecting the backlog and regulatory challenges. These prolonged timelines pose risks for companies seeking faster market entry and revenue generation.

India Biopharmaceutical Market Future Outlook

The India biopharmaceutical market is expected to show substantial growth over the next five years. This growth is driven by the increasing demand for innovative biologic therapies, continuous advancements in gene and cell therapies, and a rapidly expanding biosimilars market. Additionally, favorable government policies, such as the National Biopharma Mission, and public-private partnerships will play a key role in driving this expansion. The rising investments in biotechnology research and the development of state-of-the-art manufacturing facilities will further strengthen India's position in the global market.

India Biopharmaceutical Market Opportunities

Expanding Contract Manufacturing Organizations (CMOs): India is becoming a global hub for Contract Manufacturing Organizations (CMOs) in the biopharmaceutical sector. In 2023, the country had over 100 CMOs offering services to both domestic and international companies. With growing demand from global pharma firms to outsource biopharmaceutical production, Indias cost-efficient manufacturing and compliance with Good Manufacturing Practices (GMP) present lucrative opportunities for further expansion. The CMO market is expected to benefit from increasing outsourcing of biologics manufacturing due to rising production costs in western markets.

Biosimilar Growth Potential: India is emerging as a leader in biosimilar production, with over 95 biosimilars approved by the Drug Controller General of India (DCGI) by 2023. The rising adoption of biosimilars, particularly in therapeutic areas like oncology and autoimmune diseases, offers substantial market opportunities. With increasing healthcare costs globally, the demand for affordable biosimilars is set to rise, and Indias manufacturing capabilities provide a competitive edge to capitalize on this growing market segment.
Please Note: It will take 5-7 business days to complete the report upon order confirmation